Here is a detailed article about the Zentiva and Lupin agreement, presented in a polite and informative tone:
Zentiva and Lupin Forge Strategic Alliance for TNF-Alpha Inhibitor Biosimilar
FOR IMMEDIATE RELEASE
[City, State] – July 10, 2025 – Zentiva, a leading European pharmaceutical company, and Lupin Limited, a global pharmaceutical player headquartered in India, have announced a significant strategic collaboration. The two companies have entered into a license and supply agreement for a biosimilar medication targeting TNF-alpha inhibitors. This partnership signifies an important step forward in expanding access to vital biologic treatments for patients across Europe.
The agreement will see Zentiva license the biosimilar product from Lupin, enabling Zentiva to market and distribute the medicine under its own brand name within its extensive European network. Lupin will serve as the primary supplier of the biosimilar, leveraging its robust manufacturing capabilities and expertise in developing high-quality biosimilars.
TNF-alpha inhibitors are a critical class of biologic drugs used to treat a range of chronic inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn’s disease. By making a biosimilar version of these important therapies available, Zentiva and Lupin aim to offer more affordable treatment options, thereby increasing accessibility for a greater number of patients who can benefit from these life-changing medications.
This collaboration highlights the shared commitment of both Zentiva and Lupin to patient well-being and their strategic focus on strengthening their biosimilar portfolios. Zentiva’s established market presence and strong relationships with healthcare providers across Europe are expected to facilitate the successful introduction and uptake of the biosimilar. Simultaneously, Lupin’s proven track record in biosimilar development and manufacturing ensures a reliable supply of a high-quality product.
“We are delighted to partner with Lupin, a company that shares our dedication to improving patient lives through accessible and high-quality medicines,” said [Name and Title of Zentiva Spokesperson, if available, otherwise a general statement]. “This agreement underscores our strategy to expand our biosimilar offerings, providing valuable therapeutic options to patients and supporting healthcare systems by delivering cost-effective alternatives. We believe this collaboration will significantly benefit patients across Europe managing chronic inflammatory diseases.”
[Name and Title of Lupin Spokesperson, if available, otherwise a general statement] added, “This partnership with Zentiva is a testament to Lupin’s growing capabilities in the biosimilars space. We are proud to contribute our expertise in developing and manufacturing this TNF-alpha inhibitor biosimilar to Zentiva’s European operations. By joining forces, we aim to make a meaningful difference in the lives of patients who require these essential treatments.”
The specific terms of the agreement have not been publicly disclosed. However, the alliance is anticipated to enhance competition within the biosimilar market, ultimately benefiting patients by providing greater choice and affordability for critical therapies.
About Zentiva
Zentiva is a leading European pharmaceutical company with a mission to deliver high-quality, affordable medicines to patients. With a strong heritage and a broad portfolio of branded generics and biosimilars, Zentiva plays a vital role in supporting the healthcare needs of millions of people across Europe. The company is committed to innovation, patient access, and fostering strong partnerships to ensure sustainable healthcare solutions.
About Lupin Limited
Lupin is a global pharmaceutical company with a significant presence in the generics and biosimilars markets. Headquartered in Mumbai, India, Lupin is committed to providing affordable and accessible medicines to patients worldwide. The company has a robust research and development pipeline and a strong manufacturing infrastructure, focusing on therapeutic areas such as respiratory, cardiovascular, dermatology, and biosimilars.
Contact:
[Zentiva Media Contact Information] [Lupin Media Contact Information]
###
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
PR Newswire Healthring published ‘Zentiva und Lupin unterzeichnen Lizenz- und Liefervertrag für TNF-alpha-Inhibitor-Biosimilar-Medikament’ at 2025-07-10 05:49. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.